Title:
【発明の名称】シンノリン誘導体及びその使用
Document Type and Number:
Japanese Patent JP2000506880
Kind Code:
A
Abstract:
The invention relates to the use of cinnoline derivatives of formula (I) wherein Z represents -O-, -NH-, -S- or -CH2-; m is an integer from 1 to 5; R1 represents hydrogen, hydroxy, halogeno, nitro, cyano, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3alkylthio or NR6R7 (wherein R6 and R7, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, fluoro, chloro, methoxy, amino or nitro; R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy, C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; R4 represents hydrogen, hydroxy, halogeno, cyano, nitro, amino, trifluoromethyl, C1-3alkyl or a group R5-X1 (wherein X1 represents -O-, -CH2-, -S-, -SO-, -SO2-, -NR8CO-, -CONR9-, -SO2NR10-, -NR11SO2- or -NR12- (wherein R8, R9, R10, R11 and R12 each independently represents hydrogen, C1-3alkyl or C1-3alkoxy C2-3alkyl) and R5is an optionally substituted alkyl, carbocylic or heterocylic group which may be saturated or unsaturated and may be directly linked to the cinnoline ring or be linked via a carbon chain which may have heteroatom linking groups within it and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human being, processes for the preparation of such derivatives, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
More Like This:
Inventors:
Andrew Peter Thomas
Laurent Francois André Hennecan
Laurent Francois André Hennecan
Application Number:
JP53322097A
Publication Date:
June 06, 2000
Filing Date:
March 11, 1997
Export Citation:
Assignee:
Zeneca Limited
Zeneca Pharma Societe Anonym
Zeneca Pharma Societe Anonym
International Classes:
A61K31/00; A61K31/495; A61K31/50; A61K31/502; A61K31/5377; A61P9/00; C07D237/28; C07D401/12; C07D403/12; C07D413/12; C07D417/12; (IPC1-7): C07D237/28; A61K31/502; A61P9/00; C07D401/12; C07D403/12; C07D417/12
Attorney, Agent or Firm:
Toshio Yano (2 outside)